|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ASNSD1 |
Gene summary for ASNSD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ASNSD1 | Gene ID | 54529 |
| Gene name | asparagine synthetase domain containing 1 | |
| Gene Alias | NBLA00058 | |
| Cytomap | 2q32.2 | |
| Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | Q9NWL6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54529 | ASNSD1 | P74T-E | Human | Esophagus | ESCC | 5.27e-17 | 4.75e-01 | 0.1479 |
| 54529 | ASNSD1 | P75T-E | Human | Esophagus | ESCC | 2.07e-31 | 6.33e-01 | 0.1125 |
| 54529 | ASNSD1 | P76T-E | Human | Esophagus | ESCC | 1.87e-16 | 3.14e-01 | 0.1207 |
| 54529 | ASNSD1 | P79T-E | Human | Esophagus | ESCC | 1.92e-25 | 4.36e-01 | 0.1154 |
| 54529 | ASNSD1 | P80T-E | Human | Esophagus | ESCC | 1.23e-15 | 5.23e-01 | 0.155 |
| 54529 | ASNSD1 | P82T-E | Human | Esophagus | ESCC | 7.92e-11 | 5.83e-01 | 0.1072 |
| 54529 | ASNSD1 | P83T-E | Human | Esophagus | ESCC | 2.36e-28 | 7.54e-01 | 0.1738 |
| 54529 | ASNSD1 | P84T-E | Human | Esophagus | ESCC | 1.36e-06 | 3.79e-01 | 0.0933 |
| 54529 | ASNSD1 | P89T-E | Human | Esophagus | ESCC | 1.34e-17 | 1.06e+00 | 0.1752 |
| 54529 | ASNSD1 | P91T-E | Human | Esophagus | ESCC | 2.07e-09 | 8.79e-01 | 0.1828 |
| 54529 | ASNSD1 | P104T-E | Human | Esophagus | ESCC | 9.45e-05 | 3.26e-01 | 0.0931 |
| 54529 | ASNSD1 | P107T-E | Human | Esophagus | ESCC | 1.10e-42 | 8.78e-01 | 0.171 |
| 54529 | ASNSD1 | P126T-E | Human | Esophagus | ESCC | 5.15e-12 | 1.01e+00 | 0.1125 |
| 54529 | ASNSD1 | P127T-E | Human | Esophagus | ESCC | 1.22e-14 | 2.05e-01 | 0.0826 |
| 54529 | ASNSD1 | P128T-E | Human | Esophagus | ESCC | 3.73e-46 | 1.32e+00 | 0.1241 |
| 54529 | ASNSD1 | P130T-E | Human | Esophagus | ESCC | 2.69e-45 | 9.10e-01 | 0.1676 |
| 54529 | ASNSD1 | HCC1_Meng | Human | Liver | HCC | 4.62e-61 | 5.53e-02 | 0.0246 |
| 54529 | ASNSD1 | HCC2_Meng | Human | Liver | HCC | 1.34e-33 | 6.93e-02 | 0.0107 |
| 54529 | ASNSD1 | HCC1 | Human | Liver | HCC | 1.01e-03 | 3.17e+00 | 0.5336 |
| 54529 | ASNSD1 | HCC2 | Human | Liver | HCC | 1.17e-08 | 3.80e+00 | 0.5341 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00086525 | Esophagus | ESCC | cellular amino acid biosynthetic process | 51/8552 | 76/18723 | 1.30e-04 | 8.88e-04 | 51 |
| GO:00463948 | Esophagus | ESCC | carboxylic acid biosynthetic process | 175/8552 | 314/18723 | 1.98e-04 | 1.26e-03 | 175 |
| GO:00160538 | Esophagus | ESCC | organic acid biosynthetic process | 175/8552 | 316/18723 | 3.04e-04 | 1.82e-03 | 175 |
| GO:19016075 | Esophagus | ESCC | alpha-amino acid biosynthetic process | 45/8552 | 68/18723 | 5.13e-04 | 2.84e-03 | 45 |
| GO:00090674 | Esophagus | ESCC | aspartate family amino acid biosynthetic process | 17/8552 | 21/18723 | 1.03e-03 | 5.19e-03 | 17 |
| GO:001605321 | Liver | HCC | organic acid biosynthetic process | 200/7958 | 316/18723 | 5.24e-14 | 3.22e-12 | 200 |
| GO:004639421 | Liver | HCC | carboxylic acid biosynthetic process | 198/7958 | 314/18723 | 1.19e-13 | 6.78e-12 | 198 |
| GO:00086522 | Liver | HCC | cellular amino acid biosynthetic process | 58/7958 | 76/18723 | 1.98e-09 | 5.63e-08 | 58 |
| GO:19016052 | Liver | HCC | alpha-amino acid metabolic process | 124/7958 | 195/18723 | 2.07e-09 | 5.79e-08 | 124 |
| GO:19016072 | Liver | HCC | alpha-amino acid biosynthetic process | 53/7958 | 68/18723 | 2.62e-09 | 7.16e-08 | 53 |
| GO:00065202 | Liver | HCC | cellular amino acid metabolic process | 167/7958 | 284/18723 | 1.91e-08 | 4.56e-07 | 167 |
| GO:00090672 | Liver | HCC | aspartate family amino acid biosynthetic process | 19/7958 | 21/18723 | 6.44e-06 | 7.84e-05 | 19 |
| GO:00090662 | Liver | HCC | aspartate family amino acid metabolic process | 34/7958 | 49/18723 | 1.28e-04 | 1.06e-03 | 34 |
| GO:0009064 | Liver | HCC | glutamine family amino acid metabolic process | 47/7958 | 78/18723 | 1.17e-03 | 6.54e-03 | 47 |
| GO:00160537 | Oral cavity | OSCC | organic acid biosynthetic process | 155/7305 | 316/18723 | 1.64e-04 | 1.13e-03 | 155 |
| GO:00463947 | Oral cavity | OSCC | carboxylic acid biosynthetic process | 154/7305 | 314/18723 | 1.73e-04 | 1.19e-03 | 154 |
| GO:00086524 | Oral cavity | OSCC | cellular amino acid biosynthetic process | 42/7305 | 76/18723 | 2.93e-03 | 1.27e-02 | 42 |
| GO:19016074 | Oral cavity | OSCC | alpha-amino acid biosynthetic process | 37/7305 | 68/18723 | 7.09e-03 | 2.63e-02 | 37 |
| GO:190160711 | Oral cavity | LP | alpha-amino acid biosynthetic process | 28/4623 | 68/18723 | 2.01e-03 | 1.49e-02 | 28 |
| GO:000865211 | Oral cavity | LP | cellular amino acid biosynthetic process | 30/4623 | 76/18723 | 3.07e-03 | 2.09e-02 | 30 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ASNSD1 | SNV | Missense_Mutation | c.1792C>G | p.Leu598Val | p.L598V | Q9NWL6 | protein_coding | tolerated(0.89) | benign(0.017) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| ASNSD1 | SNV | Missense_Mutation | rs753403228 | c.1526N>A | p.Arg509His | p.R509H | Q9NWL6 | protein_coding | tolerated(0.11) | benign(0.036) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ASNSD1 | SNV | Missense_Mutation | novel | c.1826N>T | p.Arg609Ile | p.R609I | Q9NWL6 | protein_coding | deleterious(0) | probably_damaging(0.94) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ASNSD1 | SNV | Missense_Mutation | c.52G>C | p.Asp18His | p.D18H | Q9NWL6 | protein_coding | tolerated(0.12) | benign(0.023) | TCGA-AO-A1KR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| ASNSD1 | SNV | Missense_Mutation | c.451N>T | p.Gly151Cys | p.G151C | Q9NWL6 | protein_coding | deleterious(0.02) | possibly_damaging(0.52) | TCGA-GM-A2DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR | |
| ASNSD1 | SNV | Missense_Mutation | rs777711639 | c.1520G>A | p.Arg507His | p.R507H | Q9NWL6 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ASNSD1 | SNV | Missense_Mutation | c.109N>G | p.Gln37Glu | p.Q37E | Q9NWL6 | protein_coding | tolerated(0.12) | benign(0.007) | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD | |
| ASNSD1 | SNV | Missense_Mutation | c.168N>T | p.Leu56Phe | p.L56F | Q9NWL6 | protein_coding | tolerated(0.06) | benign(0.066) | TCGA-LP-A7HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ASNSD1 | SNV | Missense_Mutation | rs781735004 | c.889N>T | p.Arg297Cys | p.R297C | Q9NWL6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| ASNSD1 | SNV | Missense_Mutation | rs144391161 | c.1217G>A | p.Arg406Gln | p.R406Q | Q9NWL6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |